Multiple Therapies in Treating Patients With Advanced Neuroblastoma

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining different types of therapies may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy, monoclonal antibody therapy, surgery, peripheral stem cell transplantation, radiation therapy, and biological therapy in treating patients who have advanced neuroblastoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Antibodies; Antibodies, Monoclonal; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Isotretinoin; Liposomal doxorubicin; Sargramostim; Thiotepa; Topotecan; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of neuroblastoma by 1 of the following:

• Histologic confirmation, including immunohistochemical, ultrastructural, or cytogenetic studies

• Elevated urinary catecholamines plus tumor cells/clumps in the bone marrow

• Poor-risk disease, defined by 1 of the following:

• Stage IV disease

• Unresectable primary disease plus N-myc amplification

• Infant (under age 1) with stage IV disease plus N-myc amplification

• Previously treated disease allowed

PATIENT CHARACTERISTICS:

Age:

• 50 and under

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• No prior allergy to mouse proteins

• Not pregnant

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Prior murine antibodies allowed if human anti-mouse antibody (HAMA) titer is less than 1,000 ELISA units/mL

Chemotherapy:

• Not specified

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• See Disease Characteristics